Bristol-Myers Squibb (BMY) Says AMPLE Met Primary Endpoint in Biologic-Naïve RA Patients
Go back to Bristol-Myers Squibb (BMY) Says AMPLE Met Primary Endpoint in Biologic-Naïve RA Patients| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 66.16 -1.45 (2.14%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $67.61 | 52 Week High | $77.12 | |||
| Open | $67.23 | 52 Week Low | $49.03 | |||
| Day High | $67.54 | P/E | 42.96 | |||
| Day Low | $66.08 | EPS | $1.54 | |||
| Volume | 5,530,714 | |||||
